A carregar...
Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia
In September 2017, the US FDA announced re-approval of gemtuzumab ozogamicin (GO), a CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML). This is a very significant step toward defining new treatment regimens in AML, as the treatment...
Na minha lista:
| Publicado no: | Future Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Future Medicine Ltd
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6331698/ https://ncbi.nlm.nih.gov/pubmed/30039981 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2018-0325 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|